48 results
8-K
EX-99.1
PVCT
Provectus Biopharmaceuticals, Inc.
15 Feb 24
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
8:05am
regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health
DEFA14A
9vk5e
26 May 22
Additional proxy soliciting materials
1:26pm
DEFA14A
kcf wrngxqhres
19 May 22
Additional proxy soliciting materials
6:15am
8-K
EX-99.1
a0t1jkyeebbw4yn9mhc
19 Apr 22
Other Events
4:31pm
8-K
EX-99.1
lqm liqo6nhm2
10 Nov 14
Provectus Biopharmaceuticals PV-10 Data Presented at Sitc 29TH Annual Meeting
12:00am
8-K
EX-99.1
6lwc3714zqb
12 Jun 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
vwxak45tc5zo1ew
3 Jun 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
aawp8f3y9yt039j n6
21 May 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
x678la0 j3bd
24 Mar 14
Provectus Biopharmaceuticals Inc. Submits Application to Fda to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
12:00am
8-K
EX-99.1
nmj008woxm81x6j80sd
18 Dec 13
Regulation FD Disclosure
12:00am